Feb 08th 2013 - Edison Investment Research today published a report on MediGene entitled "Robust Reasons For RhuDex Revision". In summary, the report says:
Medigene’s decision to expand its clinical programme for RhuDex in primary biliary cirrhosis (PBC) should result in a more meaningful outcome than would have been possible under previous plans. Although the revised Phase II study will now not start until H114 (previously a Phase IIa was to start in Q113), we believe the delay should be worth it in the long run, making RhuDex a more valuable and attractive asset to support partnering and/or financing. We have pushed back our estimated launch for RhuDex in PBC by two years to 2019 and reduce our valuation by €4m to €83m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »